FDA Approved: RYBREVANT — Original Application (Janssen Biotech, Inc.)

View source ↗

Summary

FDA approved RYBREVANT (amivantamab-vmjw) from Janssen Biotech, Inc. for adults with metastatic non-small cell lung cancer with EGFR exon 20 insertion whose dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

ORIG AP for RYBREVANT (AMIVANTAMAB-VMJW)